A behind the scenes look at Google Ventures
Where Google Ventures is pinning its hopes — The search for a better way to fight cancer is unfolding quietly against the floor-to-ceiling window of a conference room in a San Francisco office building where three young men are scrutinizing a jumble of Post-it Notes.
Context & Ripple Effects
Google Ventures has spent four years building past its origins: launched in 2009 as Google's in-house fund, it fully staffed its investment team by 2010 (revealing every partner), then scaled hard in 2011 — doubling its pace to as much as $200 million a year, opening a Startup Lab for seed-funded companies, adding a 'Googlers in Residence' program, and doubling its Googleplex office space under managing partner Bill Maris.
Fortune's behind-the-scenes visit shows where that buildout is pointing: the piece centers on a design session scrutinizing Post-it Notes about better ways to fight cancer, framing life sciences as the fund's area of conviction rather than a side bet. The story traveled unusually widely for a magazine feature — syndication and social pickup ranged from Dave McClure to GV's own account — which matters because it signals both Silicon Valley's attention and the fund's willingness to be seen defining itself around health-and-biology bets rather than generic seed deals.
First-order effects
- Life-sciences startups in the Google Ventures portfolio now receive capital at the fund's doubled pace alongside in-house design and engineering support — the Startup Lab and Googlers in Residence apparatus pointed directly at cancer-related work.
- Bill Maris's fund gets a public identity distinct from Google the company: a feature-length portrait that stakes its reputation on fighting cancer, not on strategic investments for the parent.
Second-order effects
- Traditional VC firms competing for the same founders must answer a rival whose pitch bundles money with Google-grade design and engineering talent — a services arms race among investors, not just among startups.
- Other corporate venture arms face pressure to justify themselves as more than balance-sheet appendages; Google Ventures' model of selling operational help alongside checks becomes the benchmark they are measured against.
Third-order effects
- If the pattern holds, technology capital becomes a serious funding channel for life sciences, pulling biology problems into the startup economy and forcing incumbent healthcare investors to co-invest or cede the space.
- The structural endpoint is corporate venture consolidating around platform-style funds — few, large, operationally deep players — rather than the scattered strategic-investment units most corporations ran when Google entered the business in 2009.
The trend: Corporate venture capital is evolving from passive check-writing into full-service platforms that lend operators and infrastructure to portfolio companies, with Google Ventures steering its scaled-up fund toward life sciences as the proving ground.